Fight Aging! Newsletter, October 30th 2017
In this study, the researchers showed a causal link between dynamic changes in the shapes of mitochondrial networks and longevity.
The scientists used C. elegans (nematode worms), which live just two weeks and thus enable the study of aging in real time in the lab. Mitochondrial networks inside cells typically toggle between fused and fragmented states. The researchers found that restricting the worms' diet, or mimicking dietary restriction through genetic manipulation of an energy-sensing protein called AMP-activated protein kinase (AMPK), maintained the mitochondrial networks in a fused or "youthful" state. In add...
Source: Fight Aging! - October 29, 2017 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Longevity Industry Whitepapers from the Aging Analytics Agency
The Longevity International project of the Aging Analytics Agency arises from the Biogerontology Research Foundation / Deep Knowledge Ventures portion of our growing community. The various companies and non-profit initiatives associated with this part of the community - such as In Silico Medicine and the International Aging Research Portfolio - share a focus on data. Those involved are now possessed of quite a lot of information about funding, technologies, and just who is doing what in the research community and market of young biotechnology companies. Thus the Aging Analytics Agency is a consultancy that aims to put to u...
Source: Fight Aging! - October 23, 2017 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Should Value Frameworks Take A ‘ Societal Perspective ’ ?
Editor’s note: One of the authors of this post, Peter Neumann, will be discussing issues related to the post at a Health Affairs September 13 event, “Understanding The Value of Innovations In Medicine.”
In 1996, the U.S. Panel on Cost-Effectiveness in Health and Medicine recommended that analysts conducting cost-effectiveness analyses (CEAs) should perform a reference case analysis, following a set of standard methodological practices to improve comparability and quality. They further recommended that such analyses assume a societal perspective, reflecting the perspective of a decision maker allocating resourc...
Source: Health Affairs Blog - September 6, 2017 Category: Health Management Authors: Peter J. Neumann and Sachin Kamal-Bahl Tags: Costs and Spending Drugs and Medical Innovation Quality 2nd Panel on Cost-Effectiveness in Health and Medicine Source Type: blogs
5th Annual Promotional Review Committee Compliance & Best Practices
ExL Events is hosting the 5th Annual Promotional Review Committee Compliance & Best Practices conference on October 16–17, 2017 at the Wyndham Hamilton Park in Florham Park, NJ.
Promotional review professionals have been challenged by many new regulatory developments in the last four years, due to the rapid growth of social media as a marketing platform, the popularization of online regulatory submission, and the still-growing shockwaves from 1st Amendment court decisions about off-label communication.
This year’s conference convenes industry experts from AbbVie, Allergan, Daiichi Sankyo, Eli Lilly, Leo Ph...
Source: Policy and Medicine - August 25, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
A Stealth Marketer Goes Through the Revolving Door to ... the President's Council of Economic Advisors?!
Stealthy, deceptive systematicmarketing,lobbying, andpolicy advocacy campaigns on behalf of big health care organizations, often pharmaceutical, biotechnology and medical device companies, have long been a subject of Health Care Renewal. A relatively recently revealedexample was the stealth marketing campaign used by GlaxoSmithKline to sell its antidepressant Paxil. This campaign includedmanipulating andsuppressing clinical research,bribing physicians to prescribe the drug, use ofkey opinion leaders as disguised marketers, and manipulation ofcontinuing medical education. Other notable examples included Jo...
Source: Health Care Renewal - August 24, 2017 Category: Health Management Tags: conflicts of interest deception Donald Trump revolving doors stealth health policy advocacy stealth lobbying stealth marketing Source Type: blogs
15th Annual Independent Medical Education and Grants Breakthrough Summit
The Fifteenth Annual Independent Medical Education and Grants Breakthrough Summit will be held September 12 through 13, 2017 at the Sonesta Hotel in Philadelphia, Pennsylvania. The event promises to bring together supporting organizations, medical education providers, and other key stakeholders to address some of the industry-leading issues.
Attendees will gain the latest insights on how to: assess the opportunities for medical education in a value-based healthcare landscape; evaluate and weigh the benefits versus costs to incorporate innovative learning formats and the latest technologies into CME; partner with patient a...
Source: Policy and Medicine - August 24, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
How New Generation Drugs Are Targeting Depression
Two years ago, I talked with a prominent psychiatrist about what could be done for all the people who have treatment-resistant depression who do not respond — or only partially respond — to the drugs on the market today.
“We wait for better drugs to come out,” he said.
I wanted a better answer, because my experience with the newer drugs like Zyprexa (olanzapine) — atypical neuroleptics (a type of antipsychotic) that were supposed to treat bipolar disorder with fewer side effects than typical mood stabilizers like lithium and Depakote (divalproex sodium) — proved to be a disaster.
But I am c...
Source: World of Psychology - August 17, 2017 Category: Psychiatry & Psychology Authors: Therese J. Borchard Tags: Alternative and Nutritional Supplements Antidepressant Antipsychotic Depression Medications Treatment Depressive Episode Major Depressive Disorder Source Type: blogs
Fight Aging! Newsletter, August 7th 2017
Discussions of radical life extension, technological acceleration, and artificial general intelligence were far more fringe concerns back then than is now the case, but this growth in awareness isn't a coincidence. Visions slowly become reality because people work to make that happen. Technological progress is not accidental: it is led by our desires.
I should say that de Magalhães is here generous in not passing judgement on the value (or lack thereof) of most of the various ventures and classes of approach he surveys. But some approaches are definitely better than others, and to my eyes one the principal challeng...
Source: Fight Aging! - August 6, 2017 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
How The Private Sector Can Empower Entrepreneurs To Improve Global Health
For health entrepreneurs and funders, successful collaboration requires a variety of ingredients that go beyond an initial monetary investment. Strong communication, alignment of objectives, and a long-term outlook are critical for any partnership to thrive. But these collaborations require something else, too—flexibility.
When it comes to global health, we have long known that no single company, foundation, or organization has all the answers. In the past, the private sector, including corporate-giving programs and foundations, relied largely on cash and product donations tied to immediate health needs or interventions....
Source: Health Affairs Blog - August 2, 2017 Category: Health Management Authors: Caroline T. Roan and Zubaida Bai Tags: Featured GrantWatch Health Professionals Africa entrepreneurs Global Health Health Care Delivery Health Philanthropy Pfizer Foundation Pharma Source Type: blogs
Considering Juvenescence
As noted this morning, Juvenescence is the new venture fund slash business development company created by investor Jim Mellon and allies as a part of his interest in the development of real, working anti-aging medicine. No-one is getting any younger, and that includes people with the resources to do something about this state of affairs, should they finally wake up to the ongoing revolution in biotechnology and put their shoulders to the wheel. This is the latest instance of a well-heeled group setting forth in earnest to achieve something in aging research and related biotechnology relevant to treating aging as a medical ...
Source: Fight Aging! - July 31, 2017 Category: Research Authors: Reason Tags: Healthy Life Extension Community Source Type: blogs
A Few More Details on Juvenescence
Jim Mellon is making a high profile investment in the development of therapeutics to treat aging, and this article offers a few more details on the company founded to carry this forward, Juvenescence. It is good to see new funding and vigor joining the field, but by the sound of it most of the proposed work is not actually all that interesting. It will be more of the standard drug development to try to slightly slow the aging process: consider the present panoply of work on calorie restriction mimetics, enhancement of autophagy, exercise mimetics, and so forth. Billions have been spent in this area in the past two decades ...
Source: Fight Aging! - July 31, 2017 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Eliminating The Medicaid Expansion May Cause More Damage Than Congress Realizes
The American Health Care Act (AHCA) and the Senate’s ill-fated Better Care Reconciliation Act (BCRA) attempted to deliver on two promises: 1) protecting patients with preexisting conditions, and 2) eliminating the Medicaid expansion. Though repeal efforts seem to have stalled for the time being, future GOP attempts to replace the ACA will undoubtedly involve the delicate task of appeasing conservative party members while maintaining provisions of the ACA that remain immensely popular with voters. While others have already discussed the failings of the proposed legislation with respect to the Medicaid expansion and preexi...
Source: Health Affairs Blog - July 20, 2017 Category: Health Management Authors: Justin Puckett and Jalpa Doshi Tags: Featured Following the ACA Medicaid and CHIP HIV/AIDS medicaid expansion states Source Type: blogs
Building Sustainable Partnerships To Improve Access To Breast Cancer Treatment For Uninsured Women
Breast cancer is a terrifying disease for most women. In the United States, it is the leading cause of cancer deaths among women ages twenty to fifty-nine years. More than 5,100 women are diagnosed with—and at least 1,100 women die from—breast cancer in New York City each year. The breast cancer survival rate is also lower for uninsured women than for those with private health insurance coverage.
Although access to affordable breast cancer screening and treatment has grown substantially over the past few years as a result of increased health insurance coverage options through the Affordable Care Act (ACA), many uninsur...
Source: Health Affairs Blog - June 20, 2017 Category: Health Management Authors: Kumbirai M. Madondo, Janice Zaballero and José Pagán Tags: Costs and Spending Featured GrantWatch Health Professionals Insurance and Coverage Access breast cancer Consumers Health Care Costs Health Care Delivery Health Philanthropy Health Promotion and Disease PreventionGW Hospitals imag Source Type: blogs
The Battle Over Patient Assistance Programs Heats Up
This article outlines some of the recent subpoenas, with focus on the most recent subpoena to make the news, that of Pfizer.
For decades now, connecting with the patient has been the holy grail of pharmaceutical marketing. Even though drugs traditionally are marketed by influencing the learned intermediary (the doctor), companies have long struggled to reach patients. This need to reach patients is particularly the case now as patient power and sophistication have increased. However, pharmaceutical marketers have yet to find an efficient way to get to the ultimate user (the patient) without running afoul of governm...
Source: Policy and Medicine - June 20, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
Toward A New Model For Promoting The Development Of Antimicrobial Drugs
As global health leaders gather in Berlin from May 19–20 for the first-ever G20 Health Ministers’ meeting, one of the main topics of discussion is expected to be how to best fight the threat of antimicrobial resistance (AMR). This reflects the growing recognition that AMR poses a significant threat to human health. An influential 2014 report by the Review on Antimicrobial Resistance, commonly referred to as the O’Neill Commission, estimated that antimicrobial-resistant infections currently claim 700,000 lives worldwide each year, a figure that could rise to as high as 10 million deaths per year by 2050. Estimates...
Source: Health Affairs Blog - May 18, 2017 Category: Health Management Authors: Seth Seabury and Neeraj Sood Tags: Costs and Spending Drugs and Medical Innovation Population Health Antibiotics antimicrobial resistance Food and Drug Administration G20 O'Neill Commission Review on Antimicrobial Resistance Source Type: blogs
